MANNKIND CORP Business Operations Contracts & Agreements
22 Contracts & Agreements
- Administration Agreements (2 contracts)
- Collaboration Agreements (3)
- Sales Agreements (1)
- Settlement Agreements (1)
- Supply Agreements (15)
- Third Amendment to Supply Agreement, dated April 11, 2018, by and between MannKind and Amphastar Pharmaceuticals, Inc (Filed With SEC on November 7, 2024)
- Second Amendment to Supply Agreement, dated November 9, 2016, by and between MannKind and Amphastar Pharmaceuticals, Inc (Filed With SEC on November 7, 2024)
- License and Collaboration Agreement, dated September 3, 2018 by and between MannKind and United Therapeutics (Filed With SEC on February 27, 2024)
- Fourth Amendment to Commercial Supply Agreement, dated December 22, 2022, by and between MannKind Corporation and United Therapeutics Corporation (Filed With SEC on February 23, 2023)
- Third Amendment to Commercial Supply Agreement, dated August 31, 2022, by and between MannKind Corporation and United Therapeutics Corporation (Filed With SEC on February 23, 2023)
- Second Amendment to Commercial Supply Agreement, dated June 15, 2022, by and between MannKind Corporation and United Therapeutics Corporation (Filed With SEC on February 23, 2023)
- First Amendment to Commercial Supply Agreement, dated October 16, 2021, by and between MannKind Corporation and United Therapeutics Corporation (Filed With SEC on November 9, 2021)
- Commercial Supply Agreement, dated August 12, 2021, by and between MannKind Corporation and United Therapeutics Corporation (Filed With SEC on November 9, 2021)
- Supply Agreement, dated as of July 31, 2014, by and between MannKind and Amphastar France Pharmaceuticals S.A.S (Filed With SEC on February 25, 2021)
- Fourth Amendment to Supply Agreement, dated December 24, 2018, by and between MannKind and Amphastar Pharmaceuticals, Inc (Filed With SEC on February 26, 2019)
- License and Collaboration Agreement, dated September 3, 2018 by and between MannKind and United Therapeutics Corporation (Filed With SEC on November 1, 2018)
- Third Amendment to Supply Agreement, dated April 11, 2018, by and between MannKind and Amphastar Pharmaceuticals, Inc (Filed With SEC on May 9, 2018)
- Controlled Equity OfferingSM Sales Agreement, by and between MannKind and Cantor Fitzgerald & Co., dated February 27, 2018 (Filed With SEC on February 27, 2018)
- SECONDAMENDMENT TO SUPPLY AGREEMENT (Filed With SEC on March 16, 2017)
- FIRST AMENDMENT TO SUPPLY AGREEMENT (Filed With SEC on March 16, 2017)
- SETTLEMENT AGREEMENT (Filed With SEC on March 16, 2017)
- SUPPLY AGREEMENT (Filed With SEC on November 10, 2014)
- SUPPLY AGREEMENT (Filed With SEC on November 10, 2014)
- LICENSE AND COLLABORATION AGREEMENT (Filed With SEC on November 10, 2014)
- the risk of severe hypoglycemia, which is abnormally low levels of blood glucose that result from excessive insulin administration. Hypoglycemia can result in loss of mental... (Filed With SEC on February 27, 2009)
- the risk of severe hypoglycemia, which is abnormally low levels of blood glucose that result from excessive insulin administration. Hypoglycemia can result in loss of mental... (Filed With SEC on March 14, 2008)
- Supply Agreement dated December 31, 2004 between MannKind Corporation and Vaupell, Inc (Filed With SEC on February 23, 2005)
